SELLAS Life Sciences Group, Inc. business relationships
Companies named in SELLAS Life Sciences Group, Inc.’s 10-K filed 2026-03-19, and public companies whose annual reports name SELLAS Life Sciences Group, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 18 / 100 Top 2% in its category
- Agent readiness
- 20 / 100
- AI adoption
- 10 / 100
Layers: Peptides
Named in SELLAS Life Sciences Group, Inc.’s annual report 3
“In December 2018, we, in collaboration with Merck, initiated a Phase 1/2 open-label, non-comparative, multicenter, multi-arm clinical trial of GPS in combination with pembrolizumab in patients with WT1-positive advanced cancers, including both hematologic malignancies and solid tumors.” SEC filing
“...check-point inhibitor (e.g., PD-1 inhibitor), we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab with exploratory lon...” SEC filing
“We have not entered into a dedicated supply agreement with the manufacturers for GM-CSF or Montanide, and instead rely on purchase orders to meet our supply needs.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.